Mirum Pharmaceuticals Inc

NASDAQ:MIRMUnited States

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Contact Information

Headquarters

950 Tower Ln Ste 1050FOSTER CITY, CA, United States 94404-4251

Phone

650-667-4085

Fax

302-269-3855

Executives

Independent Non-Executive Chairman of the Board

Michael Grey

President, Chief Operating Officer

Peter Radovich

Chief Executive Officer, Co-Founder, Director

Christopher Peetz

Chief Financial Officer

Eric Bjerkholt

Chief Scientific Officer

Pamela Vig